Australia markets closed

Hexima Limited (HXL.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
0.01100.0000 (0.00%)
At close: 10:47AM AEST

Hexima Limited

La Trobe Institute for Molecular Science
Level 4 LIMS2 La Trobe University
Bundoora, VIC 3086
Australia
61 3 9479 1210
https://hexima.com.au

Sector(s)
Industry
Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. Helen MolloyFinancial Controller224.24kN/AN/A
Prof. Marilyn A. Anderson A.O., AO, B.Sc., BSc (Hons), FAA, FAICD, FTChief Science Officer48.63kN/A1951
Dr. Nancy Sacco Ph.D.Chief Development Officer175.25kN/AN/A
Mr. Geoffrey Paul Kempler B.Sc.MD & ChairmanN/AN/A1955
Dr. Neil ForresterVice President of Business DevelopmentN/AN/AN/A
Ms. Leanne Ralph AAICD, ACIS, BBusCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company's lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.

Corporate governance

Hexima Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.